Email this article The role of monoclonal antibodies in treatment of refractory multiple myeloma
- Authors: Ryabukhina Y.E.1, Timofeeva O.L.1, Akhov A.O.1, Abbasbeyli F.M.1, Zeynalova P.A.1,2, Sinitsyna O.V.1, Akhobekov A.A.1, Kupryshina N.A.3, Zhukov A.G.1
-
Affiliations:
- Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
- Issue: Vol 2, No 1 (2022)
- Pages: 48-57
- Section: NEW DIRECTIONS AND ADVANCEMENTS IN TREATMENT OF ONCOLOGICAL DISEASES IN THE CURRENT AGE
- Published: 04.03.2022
- URL: https://mdonco.abvpress.ru/jour/article/view/27
- DOI: https://doi.org/10.17650/2782-3202-2022-2-1-48-57
- ID: 27
Cite item
Full Text
Abstract
Multiple myeloma (MM) is a B-cell malignant tumor; its morphological substrate – plasma cells – produces monoclonal immunoglobulin. Primarily, MM is diagnosed in elderly people and is characterized by a variety of clinical manifestations caused by plasma cells infiltration and organ damage. Despite successes in MM therapy, in the majority of cases recurrences of MM or refractory process are observed. In this case, the choice of antitumor drug is usually made depending on its tolerability, toxicity, and availability. Selection of correct treatment can be complicated by such frequent clinical manifestations of MM as osteolytic vertebral lesions leading to development of pathologic compression fractures which in some cases cause spinal cord compression and full immobility in the patients with MM.
A clinical case of a 62-year-old female patient with refractory MM is presented. Pathologic compression fractures of the Th12 and L2 vertebral bodies with massive extraosseous component at the Th12 vertebra level posed a threat of spinal cord compression. At the 1st stage, percutaneous vertebroplasty was performed, then antitumor therapy with daratumumab without increased intercycle intervals which significantly increased patient’s quality of life.
About the authors
Yu. E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Author for correspondence.
Email: gemonk.yur@mail.ru
ORCID iD: 0000-0001-8443-8816
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Russian FederationO. L. Timofeeva
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
ORCID iD: 0000-0002-6229-7300
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Russian FederationA. O. Akhov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Russian FederationF. M. Abbasbeyli
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
ORCID iD: 0000-0002-2359-0547
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Russian FederationP. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
ORCID iD: 0000-0003-1564-424X
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Bld. 2, 8 Trubetskaya St., Moscow 119991; Department of Oncology
Russian FederationO. V. Sinitsyna
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Russian FederationA. A. Akhobekov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
ORCID iD: 0000-0002-6395-5790
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Russian FederationN. A. Kupryshina
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
ORCID iD: 0000-0001-8509-0954
24 Kashirskoe Shosse, Moscow 115478
Russian FederationA. G. Zhukov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
111 1st Uspenskoe Shosse, Lapino, Moscow region 143081
Russian FederationReferences
- Mendeleeva L.P., Votyakova O.M., Rekhtina I.G. et al. Multiple myeloma. Clinical recommendations. Sovremennaya onkologiya = Journal of Modern Oncology 2020;22(4):6–28. (In Russ.). doi: 10.26442/18151434.2020.4.200457.
- Bessmeltsev S.S. Multiple myeloma (pathogenesis, clinical features, diagnosis, differential diagnosis). Part I. Klinicheskaya oncogematologiya. Fundamentalniye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Basic research and clinical practice 2013;6(3):237–57. (In Russ.).
- Callander N.S., Baljevic M., Adekola K. et al. Multiple Myeloma, Version 3. 2022. Featured Updates to the NCCN Guidelines. J Natl Compr Canc Netw 2022;20(1):8–19.
- Semochkin S.V. Treatment of doublerefractory multiple myeloma. Onkogematologiya = Oncohematology 2021;16(3):58–73. (In Russ.). doi: 10.17650/1818-8346-2021-16-3-58-73.
- Valiev A.K., Sokolovsky A.V., Nered A.S., Musaev E.R. Minimally invasive surgical techniques in hematological malignancies with spinal involvement. Fundamentalniye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Basic research and clinical practice 2013;6(2):177–94. (In Russ.).
- Valiev A.K., Musaev E.R., Sushentsov E.A., Borzov K.A. Percutaneous vertebroplasty in metastatic spinal lesion. Povolzhskiy oncologicheskiy vestnik = Volga Oncological Bulletin 2012;2:50–55. (In Russ.).
- Rajkumar S.V., Dimopoulos M.A., Palumbo A. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15(12):e538–48. doi: 10.1016/S1470-2045(14)70442-5.
- Kumar S.K., Dimopoulos M.A., Kastritis E. et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 2017;31(11):2443– 8. doi: 10.1038/leu.2017.138.
- Lonial S., Weiss B.M., Usmani S. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomized, phase 2 trial. Lancet 2016;387(10027):1551–60. doi: 10.1016/S0140-6736(15)01120-4.
Supplementary files
